These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 10948356)
1. Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Toge T; Yamaguchi Y Oncol Rep; 2000; 7(5):1157-61. PubMed ID: 10948356 [TBL] [Abstract][Full Text] [Related]
2. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Niimoto M; Hattori T; Tamada R; Sugimachi K; Inokuchi K; Ogawa N Jpn J Surg; 1988 Nov; 18(6):681-6. PubMed ID: 3150019 [TBL] [Abstract][Full Text] [Related]
3. [A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer]. Nakajima T; Inokuchi K; Hattori T; Inoue K; Taguchi T; Kondo T; Abe O; Kikuchi K; Tanabe T; Ogawa N Gan To Kagaku Ryoho; 1985 Sep; 12(9):1850-63. PubMed ID: 3929694 [TBL] [Abstract][Full Text] [Related]
4. [Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer--five-year survival rate]. Nakajima T; Inokuchi K; Hattori T; Inoue K; Taguchi T; Kondou T; Abe O; Kikuchi K; Tanabe T; Ogawa N Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 1):799-806. PubMed ID: 2496668 [TBL] [Abstract][Full Text] [Related]
5. Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy. Hattori T; Nakajima T; Nakazato H; Tanabe T; Kikuchi K; Abe O; Kondo T; Taguchi T; Komi N; Sugimachi K Jpn J Surg; 1990 Mar; 20(2):127-36. PubMed ID: 2111414 [TBL] [Abstract][Full Text] [Related]
6. [An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer]. Nakazato H; Koike A; Ichihashi H; Saji S; Danno M; Ogawa N Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2563-76. PubMed ID: 2505682 [TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1). Namikawa T; Fukudome I; Ogawa M; Munekage E; Munekage M; Shiga M; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K Eur J Surg Oncol; 2015 Jun; 41(6):795-800. PubMed ID: 25887287 [TBL] [Abstract][Full Text] [Related]
8. PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients. Akagi J; Baba H Int J Clin Oncol; 2010 Apr; 15(2):145-52. PubMed ID: 20229169 [TBL] [Abstract][Full Text] [Related]
9. [A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer (II)]. Tamada R; Inokuchi K; Hattori T; Inoue K; Taguchi T; Kondo T; Abe O; Kikuchi K; Tanabe T; Nakajima T Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):716-22. PubMed ID: 3103540 [TBL] [Abstract][Full Text] [Related]
10. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1. Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128 [TBL] [Abstract][Full Text] [Related]
11. [Effect of PSK on cell-mediated immune status in the patients of stomach cancer]. Ogoshi K; Kondoh Y; Tajima T; Mitomi T Gan To Kagaku Ryoho; 1983 Mar; 10(3):811-7. PubMed ID: 6411001 [TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. Ohwada S; Ogawa T; Makita F; Tanahashi Y; Ohya T; Tomizawa N; Satoh Y; Kobayashi I; Izumi M; Takeyoshi I; Hamada K; Minaguchi S; Togo Y; Toshihiko T; Koyama T; Kamio M Oncol Rep; 2006 Apr; 15(4):861-8. PubMed ID: 16525672 [TBL] [Abstract][Full Text] [Related]
13. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Toi M; Hattori T; Akagi M; Inokuchi K; Orita K; Sugimachi K; Dohi K; Nomura Y; Monden Y; Hamada Y Cancer; 1992 Nov; 70(10):2475-83. PubMed ID: 1423177 [TBL] [Abstract][Full Text] [Related]
14. [The Clinical Role of the Neutrophil/Lymphocyte Ratio in Patients with Advanced Gastric Cancer Treated with Protein-Bound Polysaccharide K and Chemotherapy]. Namikawa T; Munekage E; Munekage M; Shiga M; Maeda H; Kitagawa H; Okamoto K; Kumon M; Kobayashi M; Hanazaki K Gan To Kagaku Ryoho; 2015 Nov; 42(12):2081-3. PubMed ID: 26805271 [TBL] [Abstract][Full Text] [Related]
15. Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. Tsujitani S; Kakeji Y; Orita H; Watanabe A; Kohnoe S; Baba H; Anai H; Maehara Y; Sugimachi K Anticancer Res; 1992; 12(3):645-8. PubMed ID: 1622120 [TBL] [Abstract][Full Text] [Related]
16. [Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer]. Mitomi T; Kyoji-Ogoshi Gan To Kagaku Ryoho; 1986 Aug; 13(8):2532-7. PubMed ID: 3090939 [TBL] [Abstract][Full Text] [Related]
17. [Long-term administration of tegafur in postoperative adjuvant chemotherapy in gastric cancer patients. Serial analysis of serum tegafur and 5-fluorouracil concentrations, and influence from PSK combination]. Tanaka T; Kitao T; Furutani M; Harada T; Hayashi S; Matsushita T; Asada I; Shirosaki H Gan To Kagaku Ryoho; 1989 Jan; 16(1):95-9. PubMed ID: 2492184 [TBL] [Abstract][Full Text] [Related]
18. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Sugimachi K; Maehara Y; Ogawa M; Kakegawa T; Tomita M Cancer Chemother Pharmacol; 1997; 40(3):233-8. PubMed ID: 9219507 [TBL] [Abstract][Full Text] [Related]
19. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan. Morimoto T; Ogawa M; Orita K; Sugimachi K; Toge T; Dohi K; Nomura Y; Monden Y; Ogawa N Eur J Cancer; 1996 Feb; 32A(2):235-42. PubMed ID: 8664034 [TBL] [Abstract][Full Text] [Related]
20. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU. Takahashi Y; Mai M; Nakazato H Anticancer Res; 2005; 25(2B):1377-84. PubMed ID: 15865094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]